Brind.

Leerink Partners affirmed an Outperform rating on AbCellera.

1 report, 1 independent Updated Jul 22

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

AbCellera Leerink partners

Keep exploring

The entities involved

AbCellera
company in Vancouver, Canada

Nothing else this week.
Leerink partners
U.S. investment bank
- Analyst firm set price targets for Leerink partners' client, Twist Bioscience, on June 26, 2026. Concurrently, the CEO sold shares due to tax withholding obligations.Mon 08:52
- A filing required by the SEC concerning McKesson Corporation shares, accompanied by analyst commentary.Sun 22:38

Coverage

Newest first; wire copies grouped

Jul 22Insider MonkeyLeerink Partners Affirms Outperform Rating on AbCellera Biologics (ABCL) Following Pivot AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the top high-return penny stocks to buy now. On July 7, Leeri